Skip to Main Content

Paper Details

Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy.
Mol Neurodegener
4
2021
AD, APP, Alzheimer's disease, EGFP, IL10, IL6, Il10, Il10 receptors, Il6, TgCRND8 APP, amyloid, anti-A1-16 mAb5 monoclonal antibody, gliosis, human, humans, interleukins, mAb5, mRNA, mice, mouse, mouse IgG, transgene
Author NameAffiliation
Yona LevitesCenter for Translational Research in Neurodegenerative Disease, and McKnight Brain Institute, University of Florida
Cory C FunkInstitute for Systems Biology
Xue WangMayo Clinic Florida
Paramita ChakrabartyCenter for Translational Research in Neurodegenerative Disease, and McKnight Brain Institute, University of Florida
Karen N McFarlandCenter for Translational Research in Neurodegenerative Disease, and McKnight Brain Institute, University of Florida
Mariet AllenMayo Clinic
Minerva M CarrasquilloMayo Clinic
Dennis W DicksonMayo Clinic
Pedro E CruzCenter for Translational Research in Neurodegenerative Disease, and McKnight Brain Institute, University of Florida
Hongdong LiCenter for Bioinformatics, Central South University
Nathan D PriceInstitute for Systems Biology
Nathan D PriceInstitute for Systems Biology
Nil??fer Ertekin-TanerMayo Clinic
Nil??fer Ertekin-TanerMayo Clinic
Todd E GoldeCenter for Translational Research in Neurodegenerative Disease, and McKnight Brain Institute, University of Florida
  • 1 - 15

Datasets

Release 1.2